These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 10759407)

  • 1. Toward checkmate: biology and breast cancer therapy for the new millennium.
    Miller KD; Sledge GW
    Invest New Drugs; 1999; 17(4):417-27. PubMed ID: 10759407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of the new biology for therapy in breast cancer.
    Sledge GW
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):76-81. PubMed ID: 8614850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth factors and their receptors.
    Tripathy D; Benz C
    Hematol Oncol Clin North Am; 1994 Feb; 8(1):29-50. PubMed ID: 8150783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Herceptin therapy in breast cancer: new indication?].
    Lebeau A
    Verh Dtsch Ges Pathol; 2006; 90():99-106. PubMed ID: 17867585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Breast cancer and polypeptide growth factors].
    Rømer J; Holst-Hansen C; Moser C; Brünner N
    Nord Med; 1992; 107(2):49-52. PubMed ID: 1538961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers.
    Gunningham SP; Currie MJ; Han C; Robinson BA; Scott PA; Harris AL; Fox SB
    Clin Cancer Res; 2000 Nov; 6(11):4278-86. PubMed ID: 11106244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
    Ross JS; Fletcher JA
    Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth factors in breast cancer.
    Dickson RB; Lippman ME
    Endocr Rev; 1995 Oct; 16(5):559-89. PubMed ID: 8529572
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor angiogenesis: biology and therapeutic prospects.
    Harris SR; Thorgeirsson UP
    In Vivo; 1998; 12(6):563-70. PubMed ID: 9891218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.
    Pegram MD; Konecny G; Slamon DJ
    Cancer Treat Res; 2000; 103():57-75. PubMed ID: 10948442
    [No Abstract]   [Full Text] [Related]  

  • 13. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer.
    Harris AL; Fox S; Bicknell R; Leek R; Relf M; LeJeune S; Kaklamanis L
    Cancer; 1994 Aug; 74(3 Suppl):1021-5. PubMed ID: 8039135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autocrine and paracrine growth regulation of breast cancer: clinical implications.
    Osborne CK; Arteaga CL
    Breast Cancer Res Treat; 1990 Jan; 15(1):3-11. PubMed ID: 2183891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor angiogenesis: new approaches to cancer therapy].
    Marmé D
    Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going.
    Schettini F; Buono G; Cardalesi C; Desideri I; De Placido S; Del Mastro L
    Cancer Treat Rev; 2016 May; 46():20-6. PubMed ID: 27057657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs.
    Dunn IF; Heese O; Black PM
    J Neurooncol; 2000; 50(1-2):121-37. PubMed ID: 11245272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.